At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,300 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Multicenter Comparison Between Ultrathin-strut Biodegradable Polymer Sirolimuseluting Stents and Durable Polymer Everolimus-eluting Stents for Patients With Acute ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
In Brief
An observational study for Coronary Artery Disease and Acute Coronary Syndrome. Completed, enrolled 1,300 participants across 10 sites.
Detailed Summary
The objective of the BIOSTEMI ES study is to assess the long-term clinical outcomes with the Orsiro ultrathin-strut biodegradable polymer sirolimus-eluting stent compared to the Xience thin-strut durable polymer everolimus-eluting stent up to 5 years of follow-up among patients with STEMI undergoing primary PCI, enrolled in the BIOSTEMI trial.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease, Acute Coronary Syndrome
CountriesSwitzerland
CollaboratorsInsel Gruppe AG, University Hospital Bern
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartOct 2021
First PostedAug 2022
Primary CompletionApr 2023
Study CompletionOct 2023
TodayJul 2026
First PostedAug 2, 2022
Enrollment StartOct 15, 2021
Primary CompletionApr 30, 2023
Study CompletionOct 28, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 3.9 years ago